Physician profile
Stacy R Loree
NPI 1740577790
$3,635.94
in general payments reported to CMS, 2019-2025
30 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $178 · 2021: $450 · 2022: $421 · 2023: $439 · 2024: $559 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $783.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $513.81 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $365.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $336.95 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $286.62 | 2019-2025 | Lifevest |
| Amgen INC. | $149.01 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $132.90 | 2019-2025 | Farxiga, Brilinta |
| Lexicon Pharmaceuticals, INC. | $124.74 | 2024 | Inpefa |
| Astellas Pharma US INC | $115.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.25 | 2024-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $78.71 | 2019-2025 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $74.68 | 2019-2021 | |
| Baxter Healthcare | $73.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $72.52 | 2019-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $45.85 | 2022-2023 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $39.04 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $37.73 | 2024-2025 | |
| Esperion Therapeutics, INC. | $30.55 | 2020-2025 | Nexletol |
| Cleerly, INC. | $29.81 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Medtronic, INC. | $28.52 | 2024 | Corevalve Evolut R |
| Amarin Pharma, INC. | $28.47 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.61 | 2021 | |
| Novo Nordisk INC | $24.90 | 2024 | Wegovy |
| Abbott Laboratories | $24.84 | 2021 | |
| United Therapeutics Corporation | $23.46 | 2025 | Tyvaso |
| Tactile Systems Technology INC | $20.85 | 2025 | Nimbl, Flexitouch Plus |
| Cvrx, INC. | $20.03 | 2024 | Barostim Neo System |
| Genzyme Corporation | $18.43 | 2019 | |
| Atricure, INC. | $18.08 | 2022 | |
| Boston Scientific Corporation | $14.41 | 2023 | Ranger |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Loree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.